Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

876 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Saavedra C, Vallejo A, Longo F, Serrano JJ, Fernández M, Gion M, López-Miranda E, Martínez-Jáñez N, Guerra E, Chamorro J, Rosero D, Velasco H, Martín A, Carrato A, Casado JL, Cortés A. Saavedra C, et al. Among authors: cortes a. Cancers (Basel). 2023 Mar 27;15(7):2000. doi: 10.3390/cancers15072000. Cancers (Basel). 2023. PMID: 37046661 Free PMC article.
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martinez-Bueno A, Gonzalez X, García A, Gener P, Mina L, Alcalá-López D, Sampayo M, Cortés J, Pérez-Garcia JM, Llombart-Cussac A, López-Miranda E. López González A, et al. Among authors: cortes j, cortes a. Cancers (Basel). 2022 Nov 29;14(23):5880. doi: 10.3390/cancers14235880. Cancers (Basel). 2022. PMID: 36497361 Free PMC article.
Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature.
Albarrán V, Chamorro J, Pozas J, San Román M, Rosero DI, Saavedra C, Gion M, Cortés A, Escalera E, Guerra E, López Miranda E, Fernández Abad M, Martínez Jañez N. Albarrán V, et al. Among authors: cortes a. Front Oncol. 2023 May 5;13:1158981. doi: 10.3389/fonc.2023.1158981. eCollection 2023. Front Oncol. 2023. PMID: 37213307 Free PMC article.
Adoptive T cell therapy for solid tumors: current landscape and future challenges.
Albarrán V, San Román M, Pozas J, Chamorro J, Rosero DI, Guerrero P, Calvo JC, González C, García de Quevedo C, Pérez de Aguado P, Moreno J, Cortés A, Soria A. Albarrán V, et al. Among authors: cortes a. Front Immunol. 2024 Mar 14;15:1352805. doi: 10.3389/fimmu.2024.1352805. eCollection 2024. Front Immunol. 2024. PMID: 38550594 Free PMC article. Review.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A; PHERGain Trial Investigators. Pérez-García JM, et al. Among authors: cortes j, cortes a. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. Lancet. 2024. PMID: 38582092 Clinical Trial.
Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.
Albarrán V, Guerrero P, de Quevedo CG, González C, Chamorro J, Rosero DI, Moreno J, Calvo JC, de Aguado PP, Alía V, Sotoca P, Barrill AM, Román MS, Álvarez-Ballesteros P, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Garrido P, Gajate P. Albarrán V, et al. Among authors: cortes a. Cancer Immunol Immunother. 2024 Aug 2;73(10):186. doi: 10.1007/s00262-024-03772-9. Cancer Immunol Immunother. 2024. PMID: 39093378 Free PMC article.
Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.
Guerrero P, Albarrán V, González-Merino C, García de Quevedo C, Sotoca P, Chamorro J, Rosero DI, Barrill A, Alía V, Calvo JC, Moreno J, Pérez de Aguado P, Álvarez-Ballesteros P, San Román M, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Guerra E, Martínez-Delfrade Í, Garrido P, Gajate P. Guerrero P, et al. Among authors: cortes a. Oncologist. 2024 Oct 19:oyae284. doi: 10.1093/oncolo/oyae284. Online ahead of print. Oncologist. 2024. PMID: 39425911 Free article.
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.
Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J. Cortés A, et al. Breast. 2024 Dec;78:103834. doi: 10.1016/j.breast.2024.103834. Epub 2024 Nov 3. Breast. 2024. PMID: 39520738 Free article. Clinical Trial.
Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors.
Moreno-Moreno E, Caniego-Casas T, Carretero-Barrio I, Cortés A, Muriel A, Domínguez-Rullán JA, Martín-Gromaz C, Moreno-Bueno G, Matías-Guiu X, Palacios J, Pérez-Mies B. Moreno-Moreno E, et al. Among authors: cortes a. Am J Surg Pathol. 2024 Sep 13;48(12):1580-7. doi: 10.1097/PAS.0000000000002308. Online ahead of print. Am J Surg Pathol. 2024. PMID: 39269025 Free PMC article.
876 results